# Precigen Inc. (PGEN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $7.10, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Precigen Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 262.5×**. Each dollar of revenue is priced at 262.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 58.2×**. The shares trade at 58.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -4.5%** (5-yr avg -17.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on invested capital: -104.1%**. Return on all capital, debt included, is -104.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -161.2%**. Each dollar of assets produces -161.2% of profit.

## Growth
- **Revenue growth (1 yr): 146.7%** (3-yr -28.9%/yr, 5-yr -21.3%/yr). Revenue grew 146.7% over the last year, against -21.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -191.5%**. Earnings per share fell 191.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 4.46**. Debt is 4.46 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Precigen Inc. holds more cash than debt.
- **Altman Z-score: 9.24**. A Z-score of 9.24 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Precigen Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 55.7%** (YTD 69.9%, 3-mo 98.3%). The shares are up 55.7% over twelve months including dividends.
- **From 52-week high: -8.0%** (137.5% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 1.26** (volatility 81%). Beta of 1.26 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PGEN · Page: https://foliofundamentals.com/stocks/pgen

Not investment advice.